Antitumor effects of mpJX administered i.v. alone were compared with those of the virus given in combination with aPD1 (mpJX+aPD1) by measuring tumor cell killing (activated caspase-3 staining16) and proliferation (phosphohistone H3 staining22) in RT2;B6 mice 5 to 20 days after treatment onset at age 13 weeks (Figure 1A). This evidence concerns the gene CASP3 and neoplasm.